Rechallenge high-dose irinotecan with UGT1A1 genotype in metastatic colorectal cancer

ABSTRACT: Interventions: Drug : According to the test result of UGT1A1, irinotecan with 300 mg/m2 and 250 mg/m2 doses of 0 defective allele and 1 defective allele, respectively, is given every 2 weeks. A determined dose of Irinotecan is mixed with 500 mL or more of normal saline, 5% glucose injection solution or electrolyte maintenance solution, and infuse it intravenously over 90 minutes. Primary outcome(s): disease control rate Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Non-RCT

DISEASE(S): Neoplasms

PROVIDER: 2513214 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR